Can-Fite BioPharma
AboutSciencePipelineInvestor InformationContact Us

About Can-Fite BioPharma

About Us

Company Leadership
- Management
- Drug Dev. Team
- Board of Directors


Board of Directors

Ilan Cohn, Ph.D., Chairman
Dr. Ilan Cohn is a co-founder of the company and it’s Chairman. Dr. Cohn is a senior partner of Reinhold Cohn & Partners the largest IP firm in Israel. He manages the life sciences and chemistry department of Reinhold Cohn, which includes a very large staff of patent attorneys, trainees, paralegals, and assistant staff. Dr. Cohn, has many years of experience in the field of patents and other intellectual property fields. Additionally, in the course of his professional career Ilan gained significant experience and expertise in turning intellectual property assets, particularly patents into a first tier asset. He holds a Ph.D. in biology. He served on the board of directors of a number of life science companies in Israel and in the USA. He was also involved in the past in management of VC funds focused on investment in the field of the life sciences. Dr. Cohn served a number of years as a co-chairman of the Biotech Committee of the US-Israeli Science and Technology Commission.
Prof. Pnina Fishman, Ph.D., CEO
Prof. Fishman is the scientific founder of the company and was previously a professor of Life Sciences and headed the Laboratory of Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center. Prof. Fishman is a very accomplished scientist and has authored or co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her scientific work was the foundation on which Can-Fite was built. This scientific work has gained recognition as one of the leading approaches for new generation therapies for cancer and other diseases. Her past managerial experience included seven years as CEO of Mor Research Application (MRA), a company that was in charge of the commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. She was also involved in the establishment and served on the Board of Directors of several life sciences technology start-ups.
Avraham Sartani, MD.
Dr. Sartani was till recently a Vice-President and Director Pharmaceutical Research and Development Division, of Recordati. Prior to joining Recordati in 1985, Dr. Sartani was in Farmitalia-carlo Erba since 1980, serving in an number of roles including the Medical Director for Europe. He is a member of a number of scientific and management societies and the author/co-author of numerous publications and patents.
Israel Shamay
Israel Shamay is an MBA graduate of the Recanati School of Business at the Tel-Aviv University and a graduate of the Technion in Haifa, faculty of Information Systems Engineering. Since 2013, established and leads the Americas Operations in MATIMOP (Israeli Industry Center for R&D), the International Operations agency of the Israeli Office of the Chief Scientist, focusing on developing and implementing cooperation platforms for industrial R&D and innovation projects in the Americas region.Formerly, as Executive Director for Cooperation with Europe, was in charge of architecting, realizing and evaluating industrial innovation cooperation frameworks at bilateral and European level, making them the major R&D cooperation instrument for Israeli industry with Europe. In 2010-2011 was Head of the EUREKA Chairmanship Program (EUREKA is Europe`s largest innovation network, with 40 member states and a number of thematic clusters led by multinational enterprises). The Israeli EUREKA chairmanship program focused on developing new financial instruments for innovative SME’s and on expanding EUREKA`s international dimension. Since 2006, in addition to managing the Israeli EUREKA office, Shamay served as Israel`s National Representative in several intentional R&D programs and also as an expert evaluator for the EU Framework Programs for R&D. He also managed the Israeli R&D collaboration with the EU Global Satellite Navigation Program – GALILEO. Before joining MATIMOP, Mr. Shamay served senior technical, marketing and executive positions in Israeli hi-tech companies operating globally, including the RAD group and Comverse Technologies. In his position as VP Marketing and Business Development in Comverse Information Systems (currently named VERINT Systems, NASDAQ: VRNT) Shamay supported the international operations of the company, and in particular strategic alliances with service providers, large enterprises and government organizations in the fields of telecom and business analytics software solutions.
Yaacov Goldman
Yaacov Goldman has served as a director since August 2017 and is a member of our audit committee, financial statements` review committee and compensation committee. Mr. Goldman provides consulting services to companies in strategic-financial areas, through his wholly owned company, Maanit-Goldman Management & Investments (2002) Ltd. Mr. Goldman also serves as a director of Golden House Ltd, Fattal Europe (Properties) Ltd., Meitav Dash Investments Ltd., Mer Telemanagement Solutions Ltd. and IceCure Medical Ltd. Until September 2016 Mr. Goldman serves as a director of Medi Power (Overseas) Public Co. Limited. Until May 2016 Mr. Goldman serves a a director of Isrotel Ltd. and Cellect Biotechnology Ltd.. Until March 2012, Mr. Goldman served as a director of Elron Electronic Industries Ltd. and Negev Ceramics Ltd. Until July 2010, Mr. Goldman served as a director of Bank Leumi Le`Israel Ltd. and until June 2009 as Chairman of ITGI Medical Ltd. Until the end of 2014, Mr. Goldman served as director of Proteologics Ltd. and Renewable Resources Ltd. and its affiliated companies. Mr. Goldman served as the Professional Secretary of the Peer Review Institute of the Certified Public Accountants Institute in Israel from October 2004 until September 2008. Commencing in 1981, Mr. Goldman worked for Kesselman & Kesselman (Israeli member firm of PricewaterhouseCoopers) for 19 years, and from 1991 until 2000, as a partner and then senior partner of such firm. From September 2000 until November 2001, Mr. Goldman served as managing director of Argoquest Holdings, LLC. From March 2002 until October 2002, Mr. Goldman acted as a consultant to a private equity initiative with Poalim Capital Markets & Investments Ltd.. Mr. Goldman holds a B.A. degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant (Israel).
Guy Regev
Mr. Guy Regev is currently the Chief Executive Officer of Shaked Global Group, a privately-held equity investment firm that provides value added capital to environmental related companies and technologies. Shaked Global Group is a major shareholder in Can-Fite BioPharma and Mr. Regev is a director of Can-Fite. Mr. Regev has over 12 years of experience in accounting, financial management and control and general management of commercial enterprises. Prior to joining Shaked, Mr. Regev was Vice President, commercial business, at Housing & Construction Holding (“HCH”), Israel’s largest infrastructure company. Between 1999 and 2001, Mr. Regev was a manager at Deloitte & Touche, Israel.